FDA Expands Mavacamten Indication to Pediatric Obstructive HCM Patients mosbey@crf.org Thu, 10/01/2026 - 13:24 Caitlin E. Cox

This month: Virtual reality calms claustrophobia, tweaking trial recruitment, multidisciplinary TAVI recovery efforts, and more.

TCTMD’s Top 10 Most Popular Stories for September 2026 mosbey@crf.org Wed, 09/30/2026 - 13:00 Caitlin E. Cox ESC 2026 captured the biggest share of our top slots, but readers were most keen to learn about the first FDA approval of AI-ECG.

Top Cardiology News for September 2026 mosbey@crf.org Wed, 09/30/2026 - 09:54 1 hour 16 minutes hence This month, the TCTMD team's picks spotlight the big picture: TAVI reimbursement, a cardiology-focused AI initiative, volume requirements for interventionalists, and the Fifth UDMI

The findings align with the PROLONG registry and bolster evidence for limiting the duration of antithrombotic therapy.

Heart Failure Clinics Often Missing Where They’re Most Needed: HFSA Report mosbey@crf.org Tue, 09/29/2026 - 16:28 Todd Neale Identifying regions with expertise can improve how patients access those best at managing the disease, Richard Soucier says.

MACE risk appeared to be higher in cases for which there was disagreement, perhaps identifying the need for a closer look.

Multimodality Imaging May Better Stratify MACE Risk in Myocarditis mosbey@crf.org Mon, 09/28/2026 - 17:10 Caitlin E. Cox A retrospective analysis shows that when CMR and FDG PET/CT findings are concordant, patients are more vulnerable to events.

The largest ethnic minority in the US faces earlier disease onset along with access issues and misconceptions about prevention.

The data support the scalability of the strategy—still, an editorial urges that ethical concerns among the public can’t be ignored.

Leaders call for removal of this outdated metric, which they say has no bearing over ongoing interventional cardiologist quality.

TCTMD's Todd Neale spoke with Warraich about the ADVOCATE program, which has its sights set on heart failure first.

Seamlessly merging the AHA’s new CV risk calculators into the country’s largest electronic health record system marks a big win.

Recurrent Stroke Rates Low 15 Years After PFO Closure mosbey@crf.org Fri, 09/25/2026 - 11:21 Todd Neale The findings align with the PROLONG registry and bolster evidence for limiting the duration of antithrombotic therapy.

Task force members emphasize the STAMP method: Screen, Triage, Address risk, Modify management, and Plan services.

AHA Statement Addresses Gaps in Hispanic CVD Care mosbey@crf.org Thu, 09/24/2026 - 13:00 L.A. McKeown The largest ethnic minority in the US faces earlier disease onset along with access issues and misconceptions about prevention.

Premature heart disease in men and women in this population stands out in a way that it doesn’t in other ethnic groups.

From February 2026: Roxana Mehran speaks with Ami Bhatt and Rohan Khera about how artificial intelligence will transform cardiology.

HF with mildly reduced EF is gone, stages are updated, and new classifications for medical and interventional therapies are introduced.

More Strokes, Especially Ischemic, With LAAO vs Medical Therapy: Meta-analysis mosbey@crf.org Wed, 09/23/2026 - 15:20 Yael L. Maxwell A drop in hemorrhagic stroke with the procedure, however, may counterbalance the findings, the authors say.

Rox Heart Replay: Why AI? mosbey@crf.org Wed, 09/23/2026 - 10:12 49 minutes 15 seconds ago From February 2026: Roxana Mehran speaks with Ami Bhatt and Rohan Khera about how artificial intelligence will transform cardiology.

‘Moderate’ Agreement Between AI and Heart Team for Complex CAD Decisions mosbey@crf.org Tue, 09/22/2026 - 15:57 Todd Neale MACE risk appeared to be higher in cases for which there was disagreement, perhaps identifying the need for a closer look.

September 2026 Dispatch for the CV Team mosbey@crf.org Tue, 09/22/2026 - 09:50 L.A. McKeown This month: Virtual reality calms claustrophobia, tweaking trial recruitment, multidisciplinary TAVI recovery efforts, and more.

Investigators stressed that the method is simple, doesn’t require ultrasound, and can be done with existing cath lab infrastructure.

The approval gives US operators a second DCB option after Agent entered the market 2-and-a-half years ago.

Outcomes Steady as Hearts Donated After Circulatory Death Rise in the US mosbey@crf.org Mon, 09/21/2026 - 15:42 Caitlin E. Cox The data support the scalability of the strategy—still, an editorial urges that ethical concerns among the public can’t be ignored.

FDA Approves Selution SLR Drug-Eluting Balloon for Coronary In-Stent Restenosis mosbey@crf.org Mon, 09/21/2026 - 15:26 Todd Neale The approval gives US operators a second DCB option after Agent entered the market 2-and-a-half years ago.

The latest UDMI aims to align classifications with pathology and clinical practice, bringing numerous changes to the 2018 version.

The data “give you pause” when considering closure, especially for women who can tolerate DOACs, Christine Albert says.

(UPDATED) Asymptomatic patients will now be covered and more flexibility has been given to heart teams for individualizing patient care.

It’s unlikely a lipid-lowering agent can directly reduce infection or malignancy, but some argue it could stop a domino effect.

SCAI Pokes ABIM Again, This Time Over Procedural Volume Requirements mosbey@crf.org Fri, 09/18/2026 - 15:49 Yael L. Maxwell Leaders call for removal of this outdated metric, which they say has no bearing over ongoing interventional cardiologist quality.

Beyond Big Hospitals: Where Cardiology Is Headed Next mosbey@crf.org Fri, 09/18/2026 - 11:02 Mandar Jagtap, DO Office-based CCTA may be a tool cardiologists practicing in rural areas can use to identify at-risk patients earlier.

Global Study Shows Success of ICDs for Preventing Sudden Death in HCM mosbey@crf.org Thu, 09/17/2026 - 16:54 Todd Neale Over the last 25 years, there have been low rates of device failures and death in patients who received an ICD.

Registry Shines Light on High ASCVD Burden in Arab Americans mosbey@crf.org Thu, 09/17/2026 - 14:31 L.A. McKeown Premature heart disease in men and women in this population stands out in a way that it doesn’t in other ethnic groups.

Multiple US health systems have been awaiting the authorization before taking the Queen of Hearts platform live.

Q&A: Haider Warraich on the Quest for Agentic AI Tools for CVD mosbey@crf.org Wed, 09/16/2026 - 16:25 Todd Neale TCTMD's Todd Neale spoke with Warraich about the ADVOCATE program, which has its sights set on heart failure first.

PREVENT Equations Now in Epic EHRs: Less ‘Friction’ for Clinicians mosbey@crf.org Wed, 09/16/2026 - 14:54 Yael L. Maxwell Seamlessly merging the AHA’s new CV risk calculators into the country’s largest electronic health record system marks a big win.

The FAME 3 Trial mosbey@crf.org Wed, 09/16/2026 - 08:56 36 minutes 44 seconds hence William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.

Doing TAVI first was noninferior to a PCI-first strategy, with experts pointing out that each timing has its advantages.

It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual care.

ESC Recommends CKD Testing in All Patients With CVD mosbey@crf.org Tue, 09/15/2026 - 16:29 Yael L. Maxwell Task force members emphasize the STAMP method: Screen, Triage, Address risk, Modify management, and Plan services.

Updated ESC Heart Failure Guideline Brings Big Changes mosbey@crf.org Mon, 09/14/2026 - 16:18 Todd Neale HF with mildly reduced EF is gone, stages are updated, and new classifications for medical and interventional therapies are introduced.

PRAGUE-26: Catheter-Directed Thrombolysis Beneficial in Intermediate-High-Risk PE mosbey@crf.org Mon, 09/14/2026 - 16:06 Caitlin E. Cox Investigators stressed that the method is simple, doesn’t require ultrasound, and can be done with existing cath lab infrastructure.

Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.